PF 4447943

Drug Profile

PF 4447943

Alternative Names: PDE9i; PF-04447943; PF-4447943

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Neuropsychotherapeutics
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sickle cell anaemia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in Belgium (PO)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in Italy (PO)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top